Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 400

1.

Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Sep 1;10(5):331-42. doi: 10.2165/11633970-000000000-00000.

PMID:
22853743
2.

Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Jul 1;10(4):261-71. doi: 10.2165/11633820-000000000-00000.

PMID:
22667992
3.
4.

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.

Berger K, Hessel F, Kreuzer J, Smala A, Diener HC.

Curr Med Res Opin. 2008 Jan;24(1):267-74.

PMID:
18053318
5.

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.

Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M.

Health Technol Assess. 2011 Sep;15(31):1-178. doi: 10.3310/hta15310. Review.

6.

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.

Schleinitz MD, Weiss JP, Owens DK.

Am J Med. 2004 Jun 15;116(12):797-806.

PMID:
15178495
7.

Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.

Chen J, Bhatt DL, Dunn ES, Shi C, Caro JJ, Mahoney EM, Gabriel S, Jackson JD, Topol EJ, Cohen DJ.

Value Health. 2009 Sep;12(6):872-9. doi: 10.1111/j.1524-4733.2009.00529.x. Epub 2009 Mar 11.

8.

[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].

Haldemann R, Lüscher TF, Szucs TD.

Praxis (Bern 1994). 2001 Mar 29;90(13):539-45. German.

PMID:
11550619
9.

Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.

Lyseng-Williamson KA, Plosker GL.

Pharmacoeconomics. 2006;24(7):709-26. Review.

PMID:
16802846
10.

Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.

Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW.

Am J Cardiol. 2012 Apr 1;109(7):1020-5. doi: 10.1016/j.amjcard.2011.11.034. Epub 2012 Jan 3.

PMID:
22221944
11.

The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.

Lindgren P, Stenestrand U, Malmberg K, Jönsson B.

Clin Ther. 2005 Jan;27(1):100-10.

PMID:
15763611
12.

[Is long-term use of clopidogrel cost-effective in high-risk atherothrombotic patients?].

Annemans L, De Wever A.

Rev Med Brux. 2009 Jan-Feb;30(1):11-22. French.

PMID:
19353938
13.

Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.

Heeg B, Damen J, Van Hout B.

Pharmacoeconomics. 2007;25(12):1063-82. Review.

PMID:
18047390
15.

Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention.

Heeg BM, Peters RJ, Botteman M, van Hout BA.

Pharmacoeconomics. 2007;25(9):769-82.

PMID:
17803335
16.

The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study.

Durand-Zaleski I, Bertrand M.

Pharmacoeconomics. 2004;22 Suppl 4:19-27. Review.

PMID:
15876009
17.

[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].

Heeg B, van Gestel A, Hout Bv, Olsen J, Haghfelt TH.

Ugeskr Laeger. 2006 Aug 28;168(35):2911-5. Danish.

PMID:
16982022
18.
19.

Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.

Beinart SC, Kolm P, Veledar E, Zhang Z, Mahoney EM, Bouin O, Gabriel S, Jackson J, Chen R, Caro J, Steinhubl S, Topol E, Weintraub WS.

J Am Coll Cardiol. 2005 Sep 6;46(5):761-9.

20.

Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness.

Ho WK, Hankey GJ, Eikelboom JW.

Expert Opin Pharmacother. 2004 Mar;5(3):493-503. Review.

PMID:
15013918

Supplemental Content

Support Center